Buy Rosart (Rosuvastatin) Teva

Rosart (Rosuvastatin) Teva

731127USD

Description

Features

Reviews

Instructions for Rosart (Rosuvastatin) pills

English product name
Rozart

Release form Rosuvastatin
tabletop film sheath, 5 mg: 28, 30, 84 or 90 pcs.
tab. film sheath, 10 mg: 28, 30, 84 or 90 pcs.
tab. film sheath, 20 mg: 28, 30, 84 or 90 pcs.
tab. film sheath, 40 mg: 28, 30, 84 or 90 pcs.

Description Rosuvastatin

The tablets are covered with a pink film shell, oval, double-convex, with an engraving of "ST 4" on one side.

1 tab.
calcium rosuvastatin 41.68 mg,
which corresponds to the contents of rosuvastatin 40 mg
Adjuvants: Cellulose microcrystalline (type 102) - 92.4 mg, Crospovidone (type A) - 28 mg, calcium hydrophosphate dihydrate - 137.2 mg, lactose monohydrate - 253.68 mg, magnesium stearate - 7.04 mg; Opadray Rose II 33G240007 ~ 16.8 mg (Hypromellose-2910 - 6.72 mg, titanium dioxide - 4.1765 mg, lactose monohydrate - 3.528 mg, macrogol-333 mg 50 - 1.344 mg, triacetine - 1.008 mg, carmine red dye - 0.0235 mg).

ATC codes
C10AA07 Rosuvastatin

Clinical-pharmacological groups / Group affiliation Rosuvastatin
Hypolipidemic drug Rosuvastatin

Active substance Rosart
rozuvastatin (calcium salt)

Pharmacotherapy group Rosuvastatin

Hypolipidemic agent - reductase inhibitor GMG-CoA

Storage Conditions Rosart
Store in a place not accessible to children at a temperature not higher than 30 ° C.

Best before date Rosart
The shelf life is

Pharmacological effect Rosart

Hypolipidemic preparation from the group of statins. A selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (GMG-CoA)-reductase, an enzyme that converts GMG-CoA into mevalonate, a precursor to cholesterol.

Increases the number of LDL receptors on the hepatocyte surface, resulting in increased LDL uptake and catabolism, inhibiting LDL synthesis, reducing the total amount of LDL and LDL. Reduces elevated concentrations of cholesterol-LDL, non-HDL cholesterol, cholesterol-LDL, total cholesterol, triglycerides (TH), TH-LDL, apolipoprotein B (ApoB), reduces cholesterol-LDL/cholesterol-HDL ratios, total cholesterol/cholesterol-HDL, cholesterol-non-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL, cholesterol-HDL apoB/apolipoprotein A-I (ApoA-I), increases cholesterol-HDL and ApoA-I concentrations.

Testimony Rosart

Primary hypercholesterolaemia (type IIa of the Fredrikson classification),
including heterozygous hereditary hypercholesterolaemia or mixed
(combined) hyperlipidemia (type IIb of the Fredrikson classification),
as a supplement to diet and other non-medicamental activities (physical exercise and reduced body weight).
Homozygous form of hereditary hypercholesterolemia with insufficient efficacy of diet and other treatments aimed at
reducing lipid concentrations (e.g. LDL-apheresis) or if such treatments are not suitable for the patient.
Hypertriglyceridemia (type IV Fredrikson) as a supplement to the diet.
To slow the progression of atherosclerosis as a supplement to diet in patients who are shown therapy to reduce the
concentration of total cholesterol and LDL cholesterol.
Primary prevention of major cardiovascular complications (stroke, heart attack, arterial revascularization) in adult
patients without clinical signs of coronary heart disease (IBS),
but with an increased risk of its development (age over 50
years for men and over 60 years for women, increased concentration of C-reactive protein (≥2 mg/L) with at least one
additional risk factor such as arterial hypertension,
low cholesterol-HDL concentration, smoking, family anamnesis of
early onset IBS).

Method of use, course and dosage Rosart

The preparation is taken inside without chewing or chopping, swallowing completely, drinking water, regardless of the time of day and food intake.

Before starting Rosart therapy, the patient should start following the standard hypolipidemic diet and continue following it during treatment.
The dose of the drug Rosuvastatin should be selected individually depending on the indications and therapeutic response, taking into account current generally accepted recommendations for target lipid concentrations. The recommended initial dose of Rozart for patients starting to take the drug, or for patients transferred from other GMG-CoA reductase inhibitors, is five or ten mg once a day. The starting dose should be guided by the patient's cholesterol concentration and the risk of developing cardiovascular complications should be taken into account, and the potential risk of developing adverse reactions should be assessed. If necessary, the dose of the drug can be increased after four weeks.

Nosology Rosart (ICD codes)